These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23307860)

  • 1. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.
    Banerjee S; Kaye SB
    Clin Cancer Res; 2013 Mar; 19(5):961-8. PubMed ID: 23307860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
    Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
    Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New perspectives in ovarian cancer treatment.
    Schmid BC; Oehler MK
    Maturitas; 2014 Feb; 77(2):128-36. PubMed ID: 24380827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising molecular targets in ovarian cancer.
    Blagden S; Gabra H
    Curr Opin Oncol; 2009 Sep; 21(5):412-9. PubMed ID: 19553815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
    McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
    J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successes and limitations of targeted cancer therapy in ovarian cancer.
    Damia G; Sessa C
    Prog Tumor Res; 2014; 41():89-97. PubMed ID: 24727989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted agents and combinations in ovarian cancer: where are we now?
    McLachlan J; Lima JP; Dumas L; Banerjee S
    Expert Rev Anticancer Ther; 2016; 16(4):441-54. PubMed ID: 26942837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
    Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
    Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications.
    Gadducci A; Guerrieri ME; Genazzani AR
    Gynecol Endocrinol; 2012 Aug; 28(8):582-6. PubMed ID: 22304686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting mTOR signaling in lung cancer.
    Marinov M; Fischer B; Arcaro A
    Crit Rev Oncol Hematol; 2007 Aug; 63(2):172-82. PubMed ID: 17540577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of targeted therapy in ovarian cancer.
    Banerjee S; Kaye S
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S116-30. PubMed ID: 21943965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
    Britten CD
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1395-409. PubMed ID: 23443307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
    Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
    Dinh P; Harnett P; Piccart-Gebhart MJ; Awada A
    Crit Rev Oncol Hematol; 2008 Aug; 67(2):103-12. PubMed ID: 18342536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.